Enabling Protein Degradation Drug Discovery

Home » News & Events

Ubiquigent appoints Professor Helen Walden and Professor John Davis to Scientific Advisory Board

Posted on July 5th, 2022 in News
Experts in structural biology and drug development will help exploit the deubiquitylase (DUB) enzyme family as new drug targets Dundee, UK, 5 July 2022: Ubiquigent Limited (Ubiquigent), a leading partner for deubiquitylase (DUB) enzyme and ubiquitin-proteasome system (UPS) focused drug… Read more

Ubiquigent celebrates milestone anniversary of DUBprofiler™ compound profiling platform

Posted on December 14th, 2021 in News
Dundee, UK, 14th December 2021: Today, Ubiquigent Limited (Ubiquigent) celebrates the 10th anniversary of its DUBprofiler™ compound profiling platform together with KSQ Therapeutics joining its expanding customer base. Over the last 10 years Ubiquigent has profiled thousands of compounds across… Read more

Ubiquigent Extends and Expands Drug Discovery Collaboration with Bristol Myers Squibb

Posted on October 26th, 2021 in News
Dundee, UK, 26th October 2021: Ubiquigent Limited (Ubiquigent) today announces the extension and expansion of its long-term collaboration with Bristol Myers Squibb.  Under the terms of the agreement, Ubiquigent will provide Bristol Myers Squibb with increased access to its deubiquitylase… Read more

Medivir licenses USP7 program to Ubiquigent

Posted on February 10th, 2021 in News
Dundee, UK 10th February 2021 — Ubiquigent Limited (Ubiquigent) announced today that it has entered into a license agreement with Medivir AB (Nasdaq Stockholm: MVIR) for Medivir’s preclinical USP7 research program. Under the terms of the agreement, Medivir has granted… Read more

Exploring the potential of DUBs and neglected tropical diseases

Posted on January 14th, 2021 in News
Ubiquigent and the University of York awarded a grant to explore the potential of novel deubiquitylase (DUB) enzyme inhibitors to address neglected tropical diseases. Dundee, UK, 14th January 2021: Ubiquigent Limited (Ubiquigent) and the Mottram Laboratory at the University of… Read more

Ubiquigent Continues Drug Discovery Collaboration with Bristol Myers Squibb

Posted on June 17th, 2020 in News
Dundee, UK, 17th June 2020: Ubiquigent Limited (Ubiquigent) today announced the continuation of a collaboration with Bristol Myers Squibb. The collaboration, originally between Ubiquigent and Celgene, will allow Bristol Myers Squibb tocapitalise on the strength and breadth of Ubiquigent’s deubiquitylase (DUB)… Read more

COVID-19 Update: Ubiquigent fully operational

Posted on April 30th, 2020 in News
Following the announcement by the UK Prime Minister and Scotland’s First Minister on the 23rd March we took the decision to temporarily close our laboratory with all staff transitioning to home working.  During this period we developed a plan that… Read more

DUBprofiler-Cell™ – target validation and compound-target engagement

Posted on January 30th, 2020 in News
Ubiquigent launches new service to facilitate target validation of deubiquitylase (DUB) enzymes and determine compound-DUB target engagement and selectivity of novel compounds in Cells Dundee, UNITED KINGDOM, 30th January 2020: Ubiquigent Limited (Ubiquigent) announced today the launch of an exciting… Read more

LEO Pharma Enters into Option Agreement with Ubiquigent for Access to Novel Compounds

Posted on October 30th, 2019 in News
Ballerup, DENMARK and Dundee, UNITED KINGDOM, 30th October 2019: Ubiquigent Limited (Ubiquigent) and LEO Pharma A/S announced today that they have entered into an option agreement granting LEO Pharma access to two novel compounds. Today’s announcement follows on from an… Read more

Targeted Protein Degradation

Posted on October 21st, 2019 in News
Ubiquigent's Scientific and Business Development Director Jason Brown will be presenting the latest developments regarding our PROTAC and molecular glue targeted protein degradation proteomics services (DUBprofiler-Cell™ and PROTEOMEprofiler™) and DUB drug discovery biology and chemistry hit-to-lead platform at the Targeted… Read more